Poor
Misaligned
Patient Risk:
Moderate
Summary
Most efficacy trial claims reference an 'ADUCEL-EXT' study and specific outcomes (24-week CWD, 'new/enlarged gadolinium-enhancing lesions', and 'inflammation in the CNS') that are not supported by the provided label excerpts. Safety and approval/patent timing claims are not supported because the provided label excerpts do not include those topics.
Category Scores
Accurate Statements
Kesimpta is approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
1 INDICATIONS AND USAGE (relapsing forms of MS including CIS, RRMS, and active SPMS in adults).
The label describes efficacy in relapsing forms of MS using annualized relapse rate (ARR) as the primary endpoint and includes MRI lesion outcomes (T1 gadolinium-enhancing lesions and new or enlarging T2 lesions).
14 CLINICAL STUDIES (primary endpoint ARR; MRI endpoints include T1 GdE lesions and new or enlarging T2 lesions).
Unsupported Statements
Kesimpta (selumetinib) is an anti-CD20 monoclonal antibody.
No support for anti-CD20 monoclonal antibody or for the named active ingredient in the provided label excerpts.
Kesimpta is effective in maintaining disease activity in patients with RRMS.
Not supported by the provided label excerpts (no statement about 'maintaining disease activity in RRMS' specifically).
Kesimpta reduces relapse rates in patients with RRMS.
The label excerpt supports relapse reduction in relapsing forms of MS generally, but RRMS is not explicitly tied to relapse outcomes within the provided excerpt wording.
In the Phase 3 clinical trial (ADUCEL-EXT), Kesimpta significantly reduced annualized relapse rates (ARRs) compared to placebo.
The provided label excerpt describes trials Study 1 and Study 2 and compares KESIMPTA to teriflunomide (not placebo), and does not mention 'ADUCEL-EXT' or placebo comparisons.
In the Phase 3 clinical trial (ADUCEL-EXT), Kesimpta significantly reduced 24-week confirmed disability worsening (CWD) rates compared to placebo.
The provided label excerpt describes 3-month confirmed disability progression and provides comparator against teriflunomide, not placebo, and does not mention '24-week' or 'ADUCEL-EXT'.
In the Phase 3 clinical trial (ADUCEL-EXT), Kesimpta significantly reduced the number of new or enlarged gadolinium-enhancing lesions.
The provided label excerpt reports T1 gadolinium-enhancing lesions and new or enlarging T2 lesions; it does not state 'new or enlarged gadolinium-enhancing lesions' or mention 'ADUCEL-EXT'.
In the Phase 3 clinical trial (ADUCEL-EXT), Kesimpta reduced inflammation in the central nervous system.
No 'CNS inflammation' outcome is described in the provided label excerpts.
A post-hoc analysis of ADUCEL-EXT found Kesimpta had similar efficacy to Tysabri (natalizumab) in reducing ARR.
The provided label excerpt does not mention 'ADUCEL-EXT' or any post-hoc comparison to natalizumab.
A post-hoc analysis of ADUCEL-EXT found Kesimpta had similar efficacy to Tysabri (natalizumab) in reducing CWD.
The provided label excerpt does not mention 'ADUCEL-EXT' or any post-hoc comparison to natalizumab.
Kesimpta was first approved in the US in 2020.
Approval date is not supported by the provided label excerpts.
Patent exclusivity for Kesimpta is expected to last until 2030.
Patent/exclusivity timeline is not supported by the provided label excerpts.
The most common adverse reactions (≥10%) with Kesimpta included injection site reactions.
Adverse reaction details are not present in the provided label excerpts.
The most common adverse reactions (≥10%) with Kesimpta included upper respiratory infections.
Adverse reaction details are not present in the provided label excerpts.
Kesimpta increases the risk of infections, including severe and life-threatening infections.
Infection risk severity language is not supported by the provided label excerpts (section 5 WARNINGS AND PRECAUTIONS was not provided).
Contradictions
Important Omissions
Key safety information cannot be verified because contraindications, boxed warnings, warnings/precautions, drug interactions, and adverse reactions sections were not provided in the label excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several efficacy claims are unsupported/misaligned with the provided label excerpts, and infection/safety claims are not supported because the relevant safety label sections were not provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Misaligned
Primary Issue
Multiple claims (study name 'ADUCEL-EXT', placebo comparisons, 24-week CWD, lesion wording, post-hoc comparisons to natalizumab, and infection/adverse reaction details) are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to what is explicitly present in the provided label excerpts: the indication wording under INDICATIONS AND USAGE and the trial outcomes under CLINICAL STUDIES comparing KESIMPTA to teriflunomide in Studies 1 and 2; avoid unsupported study identifiers and safety/adverse reaction assertions unless the corresponding label sections are provided.